News

With nearly two-thirds of the states allowing for medical cannabis use and the legalization of hemp, accessing cannabinoids has become much easier— especially for patients with cancer.

Combination therapy, selective estrogen receptor degraders, and more were covered at the 2021 San Antonio Breast Cancer Symposium.

Oral Bruton tyrosine kinase inhibitors make notable strides in CLL treatment. Chimeric antigen receptor T-cell therapy continues to command attention by besting standard-of-care therapies.

An expert discusses the consequences of cisplatin-induced hearing loss and ongoing research efforts to eliminate this associated risk for children receiving the treatment.

A nurse-driven palliative care referral intervention demonstrated preliminary success in increasing the number of patients who received this form of supportive care.

Experts from Roswell Park developed a dosing guide for the prescription of buprenorphine as treatment for chronic pain.

Since the onset of COVID-19, the United States, Brazil, India, and Russia have maintained a status of having the highest incidence of confirmed cases.

An expert with Oregon Health & Science University discusses whether Orca-T graft can fulfill an unmet need in the field of allogeneic stem cell transplantation for myelofibrosis.

The COVID-19 pandemic has affected oncology practice in many ways. What will safe treating look like moving forward?

Mark Honor, PA-C, highlights best adverse event management practices for patients undergoing chemotherapy and immune-based treatment.

Patients with treatment-naïve advanced gastrointestinal stromal tumors demonstrated promising responses following treatment with the TKI imatinib plus the MEK inhibitor binimetinib.

Frontline treatment with brentuximab vedotin and chemotherapy yielded superior survival outcomes in patients with advanced classical Hodgkin lymphoma.

Patients who underwent surveillance with bioimpedance spectroscopy were less likely to develop chronic breast cancer–related lymphedema compared with patients who were assessed with tape measure.

Although e-cigarettes are often marketed as a “safe alternative,” non-smokers should understand that smoking still poses risks of lung damage, explains an expert with CTCA.

The program is designed to reduce the age-adjusted death rate associated with cancer by at least 50% over the next 25 years.

Oncology Nursing News® meets with the lead investigator behind the phase 3 IMCgp100-202 trial to better understand the significance of tebentafusp’s approval and to determine what oncology nurses need to know about the new agent.

The oral targeted therapy was linked with maintained appetite, eating habits, and physical function in patients with IDH1-mutated cholangiocarcinoma.

Janelle Wagner, RN, OCN, Senior Manager of Patient Navigation Program for Community Sites, highlights some challenges commonly associated with nurse navigation, and how nurses can overcome them.

An expert with Stanford Health comments on the potential value of secondary cytoreductive surgery for patients with recurrent ovarian cancer and the need for careful patient selection when considering this treatment strategy.

An expert from Arizona Oncology discusses the unmet need for agents to address recurrent ovarian cancer and how upifitamab rilsodotin, an antibody-drug conjugate with promising preclinical and clinical data, may play into the treatment paradigm.

An expert from the University of California Los Angeles (UCLA) discusses the alarming rate of high-risk uterine cancers among Black women and how researchers are investigating the underlying risk factors at play.

In this episode of “The Vitals,” Dr. Janice Post-White discusses how she balanced working as an oncology nurse through her child’s cancer diagnosis, and the lessons she learned from the experience.

The FDA has expanded the prescribing information for axicabtagene ciloleucel to include prophylactic corticosteroids for all approved indications.

An expert from the University of Colorado (UC Health) comments on ongoing clinical trials which promise to shake up the treatment paradigm of endometrial cancer.

Although the long-term effects of e-smoking are still unknown, the percentage of young people developing nicotine dependency is increasing, a Cancer Treatment Centers of America expert explains.

An expert from the Ohio State University Comprehensive Cancer Center discusses whether predictive biomarkers hold the potential to change endometrial prognoses.

Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.

LAG-3 represents a potentially relevant immune checkpoint pathway in melanoma treatment.

A secondary analysis of the COACH study revealed that a geriatric assessment–guided intervention increased the number of comorbidity-related discussions between patients and providers.

The update is in agreement with the FDA approval of a labeling supplement in June 2021 to the United States Prescribing Information for neratinib in HER2-positive breast cancer.